[
    [
        {
            "time": "2018-11-05",
            "original_text": "【中银医药】医药生物行业2018年三季报综述——行业整体收入和扣非利润保持20%的增速中枢",
            "features": {
                "keywords": [
                    "医药生物",
                    "三季报",
                    "收入",
                    "扣非利润",
                    "增速"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【中银医药】医药生物行业2018年三季报综述——行业整体收入和扣非利润保持20%的增速中枢",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "【平安医药】生物医药行业2018年三季报综述：医药2018Q3收入回暖，利润承压，子行业分化加剧",
            "features": {
                "keywords": [
                    "生物医药",
                    "三季报",
                    "收入回暖",
                    "利润承压",
                    "子行业分化"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【平安医药】生物医药行业2018年三季报综述：医药2018Q3收入回暖，利润承压，子行业分化加剧",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "【平安重点】行业专题报告*生物医药*基药定义与国际接轨，新增西药市场规模近1500亿*强于大市",
            "features": {
                "keywords": [
                    "生物医药",
                    "基药",
                    "市场规模",
                    "国际接轨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【平安重点】行业专题报告*生物医药*基药定义与国际接轨，新增西药市场规模近1500亿*强于大市",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "平安研报20181105",
            "features": {
                "keywords": [],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "平安研报20181105",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "【川财研究所*常规报告】第一批境外上市临床急需新药名单发布",
            "features": {
                "keywords": [
                    "境外上市",
                    "临床急需新药",
                    "名单发布"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【川财研究所*常规报告】第一批境外上市临床急需新药名单发布",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "陷造假风波，又一高管离职，净利润三连跌，复星医药该如何“复兴”？",
            "features": {
                "keywords": [
                    "造假风波",
                    "高管离职",
                    "净利润三连跌",
                    "复星医药"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "陷造假风波，又一高管离职，净利润三连跌，复星医药该如何“复兴”？",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-11-05",
            "original_text": "医药周报:新版基药目录支持国产创新,医药板块进入配置区间",
            "features": {
                "keywords": [
                    "新版基药目录",
                    "国产创新",
                    "医药板块",
                    "配置区间"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药周报:新版基药目录支持国产创新,医药板块进入配置区间",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]